New GSK chief exec: Fewer, more focused drug programs as generic competition looms

In her 1st comments since taking the helm on April 1st, GlaxoSmithKline‘s (NYSE:GSK) new chief executive Emma Walmsley said that her priority is the company’s pharmaceuticals unit, where she wants to lead fewer but bigger new drug launches.

“We’d like to have probably fewer and more focused priorities, to have bigger launches,” she told reporters, according to Reuters. Walmsley added that this would likely involve the closure of some research programs.

This approach is a shift for the British drugmaker, which has been prolific when it comes to drug launches but has not produced any multibillion-dollar blockbuster therapies recently.

Get the full story at our sister site, Drug Delivery Business News.

The post New GSK chief exec: Fewer, more focused drug programs as generic competition looms appeared first on MassDevice.

from MassDevice http://ift.tt/2pj8HYr